A brief history of the development of antidepressant drugs: From monoamines to glutamate.

谷氨酸的 NMDA受体 抗抑郁药 重性抑郁障碍 单胺类神经递质 神经科学 医学 心理学 谷氨酸受体 精神科 药理学 心情 受体 内科学 血清素 海马体
作者
Todd M. Hillhouse,Joseph H. Porter
出处
期刊:Experimental and Clinical Psychopharmacology [American Psychological Association]
卷期号:23 (1): 1-21 被引量:556
标识
DOI:10.1037/a0038550
摘要

Major depressive disorder (MDD) is a chronic, recurring, and debilitating mental illness that is the most common mood disorder in the United States. It has been almost 50 years since the monoamine hypothesis of depression was articulated, and just over 50 years since the first pharmacological treatment for MDD was discovered. Several monoamine-based pharmacological drug classes have been developed and approved for the treatment of MDD; however, remission rates are low (often less than 60%) and there is a delayed onset before remission of depressive symptoms is achieved. As a result of a "proof-of-concept" study in 2000 with the noncompetitive NMDA antagonist ketamine, a number of studies have examined the glutamatergic systems as viable targets for the treatment of MDD. This review will provide a brief history on the development of clinically available antidepressant drugs, and then review the possible role of glutamatergic systems in the pathophysiology of MDD. Specifically, the glutamatergic review will focus on the N-methyl-D-aspartate (NMDA) receptor and the efficacy of drugs that target the NMDA receptor for the treatment of MDD. The noncompetitive NMDA receptor antagonist ketamine, which has consistently produced rapid and sustained antidepressant effects in MDD patients in a number of clinical studies, has shown the most promise as a novel glutamatergic-based treatment for MDD. However, compounds that target other glutamatergic mechanisms, such as GLYX-13 (a glycine-site partial agonist at NMDA receptors) appear promising in early clinical trials. Thus, the clinical findings to date are encouraging and support the continued search for and the development of novel compounds that target glutamatergic mechanisms.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
情怀的应助被危机的小蚂蚁采纳,获得10
1秒前
打打的应助被能干的人采纳,获得30
1秒前
duotianzhiyi完成签到,获得积分10
1秒前
怡然的复天完成签到,获得积分10
2秒前
2秒前
Hannipham完成签到,获得积分10
2秒前
上官若男的应助被开心德地采纳,获得10
3秒前
司空博涛完成签到,获得积分20
3秒前
5秒前
5秒前
洁净雅彤完成签到,获得积分10
5秒前
满意的天思完成签到 ,获得积分10
6秒前
7秒前
7秒前
7秒前
7秒前
小蘑菇的应助被WT采纳,获得10
7秒前
8秒前
李健的小迷弟的应助被O3O采纳,获得10
8秒前
9秒前
洁净雅彤发布了新的文献求助150
9秒前
已巳己发布了新的文献求助10
9秒前
华仔的应助被开心德地采纳,获得10
9秒前
10秒前
10秒前
11秒前
HouShipeng完成签到,获得积分20
12秒前
FashionBoy的应助被默默的河马采纳,获得10
13秒前
完美世界的应助被Hannipham采纳,获得10
14秒前
xr发布了新的文献求助10
14秒前
15秒前
15秒前
今后的应助被开心德地采纳,获得10
16秒前
16秒前
秋风的应助被小纪采纳,获得10
17秒前
17秒前
17秒前
18秒前
roro完成签到 ,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188371
求助须知:如何正确求助?哪些是违规求助? 9576179
关于积分的说明 21845965
捐赠科研通 7786421
什么是DOI,文献DOI怎么找? 3435292
关于科研通互助平台的介绍 2559601
邀请新用户注册赠送积分活动 2482276